Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
about
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized TrialsPrognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma.Comparison of 3D confromal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancersImpact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancerConcurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapyPerioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy.Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinomaThe Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter StudyReduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity.Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129.Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.Pharmacotherapy of head and neck cancer.Matched computed tomography segmentation and demographic data for oropharyngeal cancer radiomics challenges.Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study.The "rocky treatment course": identifying a high-risk subgroup of head and neck cancer patients for supportive interventions.Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic reviewThe Role of Transoral Robotic Surgery in the Management of HPV Negative Oropharyngeal Squamous Cell Carcinoma.Radiotherapy alone or combined with chemotherapy for base of tongue squamous cell carcinoma.Treatment de-intensification strategies for head and neck cancer.Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTNational patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma.Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma.The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma.Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial.The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer.The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.HPV-Associated Head and Neck Cancer.Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?Influence of human papillomavirus on the clinical presentation of oropharyngeal carcinoma in the United States.E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
P2860
Q30252081-5EFB0C6F-CC66-40BF-A6AC-731A0B011F5EQ30278410-5DC5F8D4-24F6-4E56-BFA9-95C37068FE20Q33742722-DF55A039-2962-4D2C-A60D-9EEAD3466261Q35142863-267F6094-A57E-42CC-9DCF-DCA62BE5A332Q35932428-9A0A2CB8-CD19-4D2A-967D-0502842AD190Q35991873-A6235CDA-99A5-43B6-A7D0-712A41257C7AQ36238876-CC504B38-60E6-40F0-8B91-0B042C4E3651Q36378279-0C29485C-8CE7-4EE9-ADF3-2E0748F69484Q36524522-7ABD7F51-7B77-4346-82AA-FEFAD15FDFAAQ36689033-7B6CA7B1-4CFE-465A-BBEF-88BC894578AFQ36834852-5CF7874B-9403-45E1-8337-5B85B9BE3300Q37193603-92E145A4-3905-4F1F-99D0-6A6EC5070975Q37319558-337F5497-A0C4-4328-824A-158EC002CFBBQ37364313-0CF13DA4-7928-44FB-8639-7D6EA3ED1516Q37436229-996A474A-7C47-477F-A918-14191FF6DFF4Q37493010-D16DD837-2F0F-4AF2-B4B2-782E54FAA3AEQ37676732-5BEB9395-EF6E-46A7-B3FB-1D4352BFAE13Q38583292-9B547DA8-C264-4C4F-84AC-82D0B3DFF97BQ38619293-6A625AF8-457D-4D23-AFD0-CDAE5D6AAF6BQ38694676-878C325A-0559-4629-B62D-A71D08807EC4Q38774532-27CF4786-EE3C-40B8-9CFF-00F4EA31A17FQ38798385-4297C3EE-C361-4288-B1E9-864537B6C9F7Q38801345-C4DDBF8A-2ECC-4B40-9ED0-06D0A11FA8A8Q38855117-A8209224-37F4-4231-ADC8-578E8B336108Q38911707-B93F30D1-60FB-42BE-8847-D085038E3344Q38944348-86AD799C-21B0-4468-94F4-8D855CB3EE67Q38984523-19BDECDD-3E34-4E59-8A58-B0054C937E4BQ39302927-3F622233-BDF9-4084-92A6-55A16F92D78FQ39370399-A54DCAE2-0616-496E-9C21-7A595C8630F9Q40046181-0E5F01AE-A4C3-4E14-A3A4-D3AF7012DC25Q40081693-7C98AE93-4DC4-4F33-B00D-5EB46806AB49Q40390118-7B64E8F4-54FE-4E9A-9491-9F075353BAAFQ40421093-258485FD-0F87-46A7-8F67-4DF3D8708051Q40465007-02674EE5-C91E-48B9-80A8-5E82B028693DQ40858416-F51F4EFD-E560-4B7A-BE2C-E46EEE4824CDQ40875373-415AF371-7526-48AA-9AC1-BD1AF9319A0FQ41201818-2906EF75-5CD6-495E-B6C6-27885A8B8CCDQ41983475-B857AA4E-37AE-47E0-98E7-10FB93FF6103Q43041829-1BDF1031-CAB1-4D2F-8F37-A2335E76CC88Q44952098-476E57E8-46C9-4C88-84FC-334A343C5ABA
P2860
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Randomized Phase III Trial to ...... eport of Efficacy and Toxicity
@nl
Randomized phase III trial to ...... port of efficacy and toxicity.
@ast
Randomized phase III trial to ...... port of efficacy and toxicity.
@en
type
label
Randomized Phase III Trial to ...... eport of Efficacy and Toxicity
@nl
Randomized phase III trial to ...... port of efficacy and toxicity.
@ast
Randomized phase III trial to ...... port of efficacy and toxicity.
@en
prefLabel
Randomized Phase III Trial to ...... eport of Efficacy and Toxicity
@nl
Randomized phase III trial to ...... port of efficacy and toxicity.
@ast
Randomized phase III trial to ...... port of efficacy and toxicity.
@en
P2093
P2860
P3181
P356
P1476
Randomized phase III trial to ...... port of efficacy and toxicity.
@en
P2093
Adam Raben
André Fortin
Christine H Chung
Craig Silverman
Denis Soulieres
Elizabeth Gore
K Kian Ang
Marcie List
Maura L Gillison
Phuc Felix Nguyen-Tan
P2860
P304
P3181
P356
10.1200/JCO.2014.55.3925
P407
P577
2014-11-03T00:00:00Z